These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 37186882)
1. Commentary: Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis. Blobner J; Tonn JC Neurosurgery; 2023 Oct; 93(4):e92. PubMed ID: 37186882 [No Abstract] [Full Text] [Related]
2. Letter: Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis. Rahman S; Ahmed Khan R; Chowdhury M; Hasan M; Haque MR; Rahman MM Neurosurgery; 2024 Apr; 94(4):e59-e60. PubMed ID: 38206039 [No Abstract] [Full Text] [Related]
3. Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis. Cheng C; Wang D; Yu M; Zhai Y; Pan C; Liang B; Zhang J; Wang C; Yin Y; Li L; Wu F; Shi Z; Fan X; Liu X; Wang Z; Zhao Z; Li G; Jiang T; Zhang W; Neurosurgery; 2023 Oct; 93(4):802-812. PubMed ID: 37070826 [TBL] [Abstract][Full Text] [Related]
5. Histone H3.3 G34-mutant Diffuse Gliomas in Adults. Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809 [TBL] [Abstract][Full Text] [Related]
6. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431 [TBL] [Abstract][Full Text] [Related]
7. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324 [TBL] [Abstract][Full Text] [Related]
8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
9. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas. Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887 [TBL] [Abstract][Full Text] [Related]
10. Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift? Scott JG; Basanta D; Chinnaiyan P; Canoll P; Swanson KR; Anderson AR Neuro Oncol; 2011 Dec; 13(12):1262-4. PubMed ID: 21784755 [No Abstract] [Full Text] [Related]
11. Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities? Mustafa DA; Swagemakers SM; Buise L; van der Spek PJ; Kros JM Acta Neuropathol Commun; 2014 Jan; 2():6. PubMed ID: 24405933 [No Abstract] [Full Text] [Related]
13. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas. Mo H; Magaki S; Deisch JK; Raghavan R J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894 [TBL] [Abstract][Full Text] [Related]